| 产品描述: | PAK抑制剂;PAK Inhibitors;产品介绍:KPT 9274 ( ATG-019) 是一种具有口服活性的小分子化合物,是非竞争性的PAK4和NAMPT双重抑制剂。在cell-free的酶活实验中,对NAMPT的IC50值约为120 nM。;InformationKPT 9274 ( ATG-019) KPT 9274 ( ATG-019) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT . It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.TargetsPAK4 (Cell-free assay); NAMPT (Cell-free assay) ; ~120 nMIn vitroKPT-9274 interferences with PAK4 and NAD biosynthetic pathways results in reduction of G2/M transit as well as induction of apoptosis and decrease in cell invasion and migration in several human RCC cell lines. The inhibition of the PAK4 pathway by KPT-9274 attenuates nuclear β-catenin as well as the Wnt/β-catenin targets cyclin D1 and c-Myc.In vivoKPT-9274 administration to a 786-O (VHL-mut) human RCC xenograft model leads to dose-dependent inhibition of tumor growth with no apparent toxicity. It also shows remarkable anti-tumor activity in sub-cutaneous xenograft models of pancreatic ductal adenocarcinoma (PDAC) cell lines and cancer stem cells as a single agent. KPT-9274 possesses desirable PK properties and is well tolerated in mice with the absence of any signs of toxicity when 200 mg/kg daily is administered either intravenously or orally.Cell Research(from reference)Cell lines:786-0, ACHN, Caki-1 and U-2 OS cells Concentrations:1μM and 5μM Incubation Time:12 hours |
| 体内研究: |
Padnarsertib 显示出与 Sunitinib 相当的减少异种移植物生长的效力。Padnarsertib 对正常人 RPTEC 的影响很小,在体内没有明显的毒性。 Padnarsertib (口服;100 mg/kg 或 200 mg/kg;一天两次;共 14 天) 导致动物模型中异种移植物生长下降,且不显著影响动物体重。8 小时后,实验结束时,测定小鼠血浆和肿瘤中的浓度分别为 10757 ng/mL 和 10647 ng/mL。 |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.638 ml |
8.188 ml |
16.377 ml |
| 5 mM |
0.328 ml |
1.638 ml |
3.275 ml |
| 10 mM |
0.164 ml |
0.819 ml |
1.638 ml |
| 50 mM |
0.033 ml |
0.164 ml |
0.328 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |